New study finds almost 50% more IUDs, implants dispensed after B.C. made birth control free
More people started using IUDs and implants after B.C. made almost all forms of prescription birth control free, according to a new UBC research study.
The study, led by Dr. Laura Schummers, found a 49 per cent jump in the number of "long-acting reversible contraceptives" (LARC) dispensed per month, 15 months after B.C.'s free contraception program began in April 2023.
"This really tells us that there was a substantial cost-related barrier to using contraception as a whole," said Schummers, assistant professor at the University of B.C. in the faculty of pharmaceutical sciences.
That "LARC" category — the most effective type of birth control — includes the IUD (intrauterine device), which is placed directly into the uterus, and the subdermal arm implant, placed under the skin in the upper arm. The implant lasts for three years, while the IUD can last for up to 12 years.
The study found an additional 11,375 people using those methods within 15 months of the policy taking effect.
Schummers said it shows that people across age groups and demographics will prefer more effective contraceptive methods when costs are removed.
An IUD can cost between $350 and $450 in Canada, and the upfront cost can be a barrier, according to Schummers.
Schummers said B.C.'s "landmark" policy has influenced discussions around free prescription medications in Canada. She noted Manitoba also started a free contraception program in October 2024.
"Nearly a 50 per cent increase ... in the context of evaluating policy changes is huge," Schummers said.
"This is not a few people at the margins whose insurance coverage wasn't quite right. This is telling us that there's a broad need for this kind of broad coverage, not just a limited sort of Band-Aid to maybe change an income threshold for coverage availability."
The research study used two data sources, including a national database to look at prescriptions across B.C. for LARC and all contraception, as well as consider that data against a control group including all the other Canadian provinces that didn't make contraception free.
Dr. Renée Hall, medical director of Willow Reproductive Health Centre in Vancouver, said her experience at the clinic tracks with the study's findings.
"There has been a significant increase since universal contraceptives started," she said.
The clinic has actually created a new phone line specifically for people calling in for long-acting reversible contraceptives like the IUD and implant.
Hall said that the universal contraception program has given patients the chance to find the best contraceptive for them.
"If the IUD didn't work out … they could easily switch to another until they found the one that could work," she said, "whereas that's really difficult to do if you have to pay the $400 for your first IUD and then another $200 for the next one."
Hall said that she recommends more training for IUD insertion, which she said is "still a little bit lacking in our usual medical programs."
Hall said the study shows the public wants access to effective, long-acting birth control.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
4 minutes ago
- CTV News
Toxic drug deaths in B.C. down in May, June, coroner says
People take part in a rally in Victoria, B.C., on April 14, 2022. THE CANADIAN PRESS/Chad Hipolito The number of deaths due to toxic drugs fell to below 150 people per month for May and June in British Columbia, a downward trend from the same months last year. The BC Coroners Service says in a statement that the province recorded 145 deaths in May compared with 181 for the same month last year. There were 147 overdose deaths in June, down from 185 the year before. The BC Coroners Service and government have also started releasing the occupation of those who died, and the two most common jobs are trades, transport and equipment operation, as well as sales and service. The statement says 69 per cent of the drug-toxicity deaths are adult men between the ages of 30 and 59, while 78 per cent of all deaths are male. The statistics show that the opioid fentanyl is the most common substance detected in those who died this year, followed by methamphetamine and cocaine. 'Forty-seven per cent of deaths reported occurred in a private residence, compared with 21 per cent outdoors,' the statement says. Smoking continues to be the primary mode of consumption of unregulated toxic drugs, with 64 per cent of investigations indicating the person who died smoked their substances, the statement says The highest toxic drugs death rate this year is in the Northern Health region with 44 deaths per 100,000 people, and the cities with the highest tolls are Vancouver, Surrey and Greater Victoria. This report by The Canadian Press was first published July 31, 2025.
National Post
34 minutes ago
- National Post
Chris Selley: Canadians discover (again) the sometimes deadly calculations of medicare
The case of 10-year-old Charleigh Pollock, the only person in British Columbia currently suffering from Batten disease — an incurable illness that attacks the nervous system — offers a very useful window into how Canada's health-care systems really work. Whether we want to look through that window is another matter. Article content The treatment Charleigh was receiving costs roughly $850,000 per year. It might extend her life expectancy past 12, which is the normal upper limit for children suffering from the disease. But B.C.'s Expensive Drugs for Rare Diseases Committee, which decides which such drugs should be funded and which should not (every province has an equivalent panel) had determined that the treatment was no longer effective, and cut her off. Article content This did not go over well. Opposition politicians, pundits and random social media users alike were practically incandescent. British Columbians 'were horrified by a system that chose cold, heartless logic over showing mercy to a dying girl in the short time she has left,' one provincial columnist, Rob Shaw, fumed at online news site Business Intelligence for B.C. Article content Article content B.C. Conservative Leader John Rustad weighed in: 'What is the point of B.C.'s Canadian healthcare system, if it's not there for families when they need it?' Article content Nevertheless, for ages, Premier David Eby and Health Minister Josie Osborne publicly deferred to the committee's expertise. But when the political pressure became too much, they folded, apologizing profusely to the Pollock family. And they didn't just overrule the committee's decision; they basically threw the committee under the bus. 'There's no question in terms of the Charleigh case that the public was not served by the current structure that we have,' Eby said Monday. 'The current structure of a committee that doesn't speak to the media, doesn't speak to the public, makes decisions behind closed doors, only speaks to the treating physician, and even then only through the Ministry of Health, resulted in a scenario where it appeared as though what was happening was the exact opposite of what anybody wants.' Article content Article content At last report, 10 members of the committee had resigned, apparently in protest at having their expertise undermined. Hard to blame them. It's not as though it's a fun job they signed up for, denying treatment to people on grounds of cost. Article content Article content Transparency is always a good thing. If our health-care systems are denying coverage for very expensive drugs for very rare diseases, we deserve to know why. But it's very easy to figure why the members of this committee are typically anonymous, and why they don't talk to the media: As Charleigh's case shows, these decisions make people very angry at the decision-makers, however medically defensible they might be. The committee's job is precisely to make hard-hearted decisions. And in every single case of someone being denied coverage, all the media would want to know is how the committee could possibly be so heartless and cruel, and when will it change its mind? Article content The central problem is that no politician will ever dare speak the truth: the 'universal' in universal health care refers to every person, not every single remedy for every single disease that's out there. If we said 'yes' to everything based on emotions, Canadian health care would be even less solvent and sustainable than it is now. Article content If that sounds heartless, that's because it is. Public health-care systems around the world rely on this sort of background heartless logic. Private health insurance in the United States doesn't cover every single expensive treatment for every single rare disease; why would public health insurance in Canada? Article content To her credit, one ex-member of the committee came out publicly, guns blazing. The government 'systematically undercut the principle of evidence-based medicine,' Dr. Sandra Sirrs told the Victoria Times-Colonist. She bristled at the notion the committee lacks compassion. 'You have no idea the amount of consideration and thoughtful discussion (that went into the decision),' she said. 'We want Charleigh not to have that disease, and if we couldn't have that, what we want is a drug that reverses the changes she suffered from Batten disease. Article content 'And if we can't have that, we at least would want a drug that, once started, prevents her from getting worse with Batten disease — and we have none of those.' Article content Is some marginal benefit, a few extra months or years of life, worth $850,000 a year to the Canadian taxpayer? It feels horrible even asking the question, which is why no one wants to talk about it. But it's a question that needs to be asked. These newly resigned committee members could do a lot of good by explaining publicly, without spin, why these bodies exist in the first place. Article content
National Post
34 minutes ago
- National Post
Altasciences and VoxCell BioInnovation Announce Strategic Collaboration to Advance Preclinical Drug Development
Article content LAVAL, Québec — Altasciences, a fully integrated drug development solution company, and VoxCell BioInnovation ('VoxCell'), a leader in 3D bioprinting and human-like tissue modeling, are pleased to announce a strategic collaboration aimed at enhancing preclinical research and accelerating the path from discovery to clinical trials. Article content This partnership combines Altasciences' comprehensive early-phase drug development capabilities with VoxCell's cutting-edge 3D tissue technology to offer a more predictive and human-relevant preclinical testing environment. By integrating VoxCell's high-resolution 3D bioprinted tissue platforms into Altasciences' discovery and preclinical services, both companies aim to reduce R&D timelines and increase the success rate of investigational therapies. Article content 'We're proud to partner with VoxCell BioInnovation to bring next-generation tissue modeling into the early stages of drug development,' Article content said Steve Mason, Co-Chief Operating Officer at Altasciences. Article content 'This collaboration aligns with our commitment to the 3Rs as well as to innovative, efficient solutions that improve data quality and accelerate decisions for our clients.' Article content VoxCell's proprietary bioprinted tissues are engineered to closely mimic the complexity of human tumors and other biological structures, offering drug developers an advanced platform for evaluating efficacy, safety, and toxicity—before moving into animal or human studies. Article content 'Our mission has always been to make drug screening more human-relevant and predictive,' Article content said Karolina Valente, CEO of VoxCell BioInnovation. Article content 'Altasciences shares this forward-thinking approach, and we're excited to work together to support pharmaceutical and biotech companies in making faster, more informed decisions.' Article content The collaboration will focus initially on drug screening for ocular indications, with plans to expand into additional therapeutic areas and applications. Article content This partnership represents a shared vision: to transform early-stage research through innovation, integration, and smarter science—delivering better outcomes for patients worldwide. Article content About Altasciences Article content Altasciences Article content preclinical Article content and Article content clinical pharmacology Article content studies, including Article content formulation, manufacturing, and analytical services Article content . For over 30 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include Article content , Article content clinical pharmacology and proof of concept Article content , Article content bioanalysis Article content , program management, Article content research support Article content , medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit Article content . Article content About VoxCell BioInnovation Article content VoxCell BioInnovation Article content is a biotechnology startup founded in 2020 in Victoria, British Columbia, Canada. The company is dedicated to advancing the future of in vitro modeling by creating novel testing platforms for oncology research and drug development. Article content VoxCell develop 3D bioprinted vascularized human-like tissue models that closely replicate native biology, offering a powerful tool for predictive, physiologically relevant research. Using a proprietary high-resolution bioprinter, advanced vascularization software, and Universal Bioinks™, they produce complex tissue models that mirror patient biopsy samples in structure and function. Article content Article content Article content Article content Contacts Article content Article content
